SCHEMBL5158352

SCHEMBL5158352

CC(C)(C)OC(=O)CC(=O)c1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.52
HPGDS O60760 1/20 0.51
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 1/20 0.49
CFTR P13569 1/20 0.49
TRPV1 Q8NER1 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HDAC4 P56524 2/20 0.44
HDAC1 Q13547 2/20 0.44
BCAT1 P54687 1/20 0.43
PPARA Q07869 1/20 0.43
KDR P35968 1/20 0.43
NOTUM Q6P988 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC7 Q8WUI4 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160062 0.86 MGAM (0.58) MGAMHPGDSKDM4ECFTRKMT2A
SCHEMBL5158122 0.83 MGAM (0.54) MGAMHPGDSKDM4EALDH1A1CFTR
SCHEMBL30475688 0.82 MGAM (0.59) MGAMHPGDSKDM4ECFTRTRPV1
SCHEMBL4770793 0.82 MGAM (0.59) MGAMHPGDSKDM4ECFTRTRPV1
SCHEMBL5158142 0.82 MGAM (0.52) MGAMHPGDSKDM4EALDH1A1CFTR
SCHEMBL9700485 0.80 MGAM (0.61) MGAMHPGDSKDM4ECFTRTRPV1
SCHEMBL6421336 0.79 HDAC1 (0.48) MGAMHPGDSKDM4EHDAC4HDAC1
SCHEMBL5363975 0.79 MGAM (0.68) MGAMHPGDSKDM4EALDH1A1CFTR
SCHEMBL6241356 0.78 KDM4E (0.48) MGAMKDM4EALDH1A1CFTRTRPV1
SCHEMBL5161544 0.78 MGAM (0.58) MGAMHPGDSKDM4ECFTRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO MGAM 323/4885HPGDS 1562/4885KDM4E 862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.